Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Following their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life Chemicals have partnered for a second time to discover de novo generated selective dual EGFR/FGFR1 inhibitors.
Accelerating the Discovery of Brain-Penetrant ATR Inhibitors with Enki™
Variational AI partnered with Rakovina Therapeutics to support the discovery of a brain-penetrant ATR inhibitor using our Enki™ generative AI platform. By generating and prioritizing novel, CNS-targeting compounds aligned with a complex target product profile, Enki helped accelerate Rakovina’s transition from in silico design to preclinical testing—demonstrating how AI can advance oncology programs facing challenging design constraints.
How to drug a novel target in 500 molecules
Research conducted by the Variational AI team: Marshall Drew-Brook, Peter Guzzo, Ahmad Issa, Mehran Khodabandeh, Sara Omar, Jason Rolfe, and Ali Saberali. Searching through the space of synthesizable molecules to find an effective drug candidate is one of the most time-consuming and expensive steps of drug discovery. Once a protein mediating disease has been identified and some […]
